Target Healthcare REIT (LON:THRL) Stock Price Passes Above 50-Day Moving Average - Time to Sell?

Key Points

• During Wednesday trading the shares briefly crossed above its 50‑day moving average (50 DMA GBX 104.03), reaching GBX 105 intraday, though the last trade was GBX 99.70 on heavy volume (~12.7M shares).
• Valuation and earnings show a market cap of £618.38M with a P/E of 10.16 and PEG 1.48; last quarterly EPS was GBX 3.38 and analysts forecast about 6.22 EPS for the year.
• Target Healthcare REIT focuses on income and growth from a portfolio of modern, purpose‑built UK care homes, diversified by tenant, geography and resident payment profile.

Target Healthcare REIT (LON:THRL - Get Free Report) shares crossed above its 50 day moving average during trading on Wednesday . The stock has a 50 day moving average of GBX 104.03 and traded as high as GBX 105. Target Healthcare REIT shares last traded at GBX 99.70, with a volume of 12,694,726 shares trading hands.

Target Healthcare REIT Stock Performance

The company has a market capitalization of £618.38 million, a PE ratio of 10.16, a PEG ratio of 1.48 and a beta of 0.68. The stock has a fifty day moving average of GBX 104.03 and a 200 day moving average of GBX 98.76.

Target Healthcare REIT (LON:THRL - Get Free Report) last announced its quarterly earnings data on Wednesday, March 18th. The company reported GBX 3.38 earnings per share (EPS) for the quarter. Target Healthcare REIT had a net margin of 104.45% and a return on equity of 10.73%. As a group, equities analysts predict that Target Healthcare REIT will post 6.2219101 EPS for the current year.

Target Healthcare REIT Company Profile

Our investment objective is to provide shareholders with an attractive level of income together with the potential for capital and income growth, from a portfolio of UK care homes, diversified by tenant, geography, and resident payment profile. We only invest in modern, purpose-built homes.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.